radiation oncology

Penn Medicine and IBA have announced a joint venture aimed at advancing proton therapy and radiation oncology program development worldwide. The partnership will combine the University of Pennsylvania health system's clinical expertise with the Belgian company's proton therapy technology to help institutions globally develop advanced cancer treatment programs. The news was picked up by international outlets including The Manila Times, reflecting interest in the global expansion of this cancer care technology.

Radiation oncology expert Eric Deutsch says science is expanding rapidly at the intersection of radiation therapy, immunology, and technology, as combined approaches such as radiotherapy paired with immunotherapy gain ground in cancer treatment. His remarks highlight how technological advances and immune-based research are reshaping how clinicians think about radiation's role beyond tumour destruction.